195 related articles for article (PubMed ID: 33260630)
21. Structural basis of recognition of interferon-α receptor by tyrosine kinase 2.
Wallweber HJ; Tam C; Franke Y; Starovasnik MA; Lupardus PJ
Nat Struct Mol Biol; 2014 May; 21(5):443-8. PubMed ID: 24704786
[TBL] [Abstract][Full Text] [Related]
22. Oncogenic TYK2 P760L kinase is effectively targeted by combinatorial TYK2, mTOR and CDK4/6 kinase blockade.
Woess K; Macho-Maschler S; Van Ingen Schenau DS; Butler M; Lassnig C; Valcanover D; Poelzl A; Meissl K; Maurer B; Brandstoetter T; Vogl C; Koren A; Kubicek S; Orlova A; Moriggl R; Strobl B; Sexl V; Van Leeuwen FN; Kuiper RP; Mueller M
Haematologica; 2023 Apr; 108(4):993-1005. PubMed ID: 35021603
[TBL] [Abstract][Full Text] [Related]
23. Specific contribution of Tyk2 JH regions to the binding and the expression of the interferon alpha/beta receptor component IFNAR1.
Richter MF; Duménil G; Uzé G; Fellous M; Pellegrini S
J Biol Chem; 1998 Sep; 273(38):24723-9. PubMed ID: 9733772
[TBL] [Abstract][Full Text] [Related]
24. The human papilloma virus (HPV)-18 E6 oncoprotein physically associates with Tyk2 and impairs Jak-STAT activation by interferon-alpha.
Li S; Labrecque S; Gauzzi MC; Cuddihy AR; Wong AH; Pellegrini S; Matlashewski GJ; Koromilas AE
Oncogene; 1999 Oct; 18(42):5727-37. PubMed ID: 10523853
[TBL] [Abstract][Full Text] [Related]
25. TYK2 kinase activity is required for functional type I interferon responses in vivo.
Prchal-Murphy M; Semper C; Lassnig C; Wallner B; Gausterer C; Teppner-Klymiuk I; Kobolak J; Müller S; Kolbe T; Karaghiosoff M; Dinnyés A; Rülicke T; Leitner NR; Strobl B; Müller M
PLoS One; 2012; 7(6):e39141. PubMed ID: 22723949
[TBL] [Abstract][Full Text] [Related]
26. Tyrosine phosphorylation of protein kinase D2 mediates ligand-inducible elimination of the Type 1 interferon receptor.
Zheng H; Qian J; Baker DP; Fuchs SY
J Biol Chem; 2011 Oct; 286(41):35733-35741. PubMed ID: 21865166
[TBL] [Abstract][Full Text] [Related]
27. Intracellular signal transduction of interferon on the suppression of haematopoietic progenitor cell growth.
Kato K; Kamezaki K; Shimoda K; Numata A; Haro T; Aoki K; Ishikawa F; Takase K; Ariyama H; Matsuda T; Miyamoto T; Nagafuji K; Gondo H; Nakayama K; Harada M
Br J Haematol; 2003 Nov; 123(3):528-35. PubMed ID: 14617019
[TBL] [Abstract][Full Text] [Related]
28. Germline activating TYK2 mutations in pediatric patients with two primary acute lymphoblastic leukemia occurrences.
Waanders E; Scheijen B; Jongmans MC; Venselaar H; van Reijmersdal SV; van Dijk AH; Pastorczak A; Weren RD; van der Schoot CE; van de Vorst M; Sonneveld E; Hoogerbrugge N; van der Velden VH; Gruhn B; Hoogerbrugge PM; van Dongen JJ; Geurts van Kessel A; van Leeuwen FN; Kuiper RP
Leukemia; 2017 Apr; 31(4):821-828. PubMed ID: 27733777
[TBL] [Abstract][Full Text] [Related]
29. Tyrosine kinase 2 is not limiting human antiviral type III interferon responses.
Fuchs S; Kaiser-Labusch P; Bank J; Ammann S; Kolb-Kokocinski A; Edelbusch C; Omran H; Ehl S
Eur J Immunol; 2016 Nov; 46(11):2639-2649. PubMed ID: 27615517
[TBL] [Abstract][Full Text] [Related]
30. Tyrosine kinase 2 - Surveillant of tumours and bona fide oncogene.
Leitner NR; Witalisz-Siepracka A; Strobl B; Müller M
Cytokine; 2017 Jan; 89():209-218. PubMed ID: 26631911
[TBL] [Abstract][Full Text] [Related]
31. Limitin, an interferon-like cytokine, transduces inhibitory signals on B-cell growth through activation of Tyk2, but not Stat1, followed by induction and nuclear translocation of Daxx.
Aoki K; Shimoda K; Oritani K; Matsuda T; Kamezaki K; Muromoto R; Numata A; Tamiya S; Haro T; Ishikawa F; Takase K; Yamamoto T; Yumioka T; Miyamoto T; Nagafuji K; Gondo H; Nagafuchi S; Nakayama K; Harada M
Exp Hematol; 2003 Dec; 31(12):1317-22. PubMed ID: 14662340
[TBL] [Abstract][Full Text] [Related]
32. Spleen tyrosine kinase (Syk) deficiency in childhood pro-B cell acute lymphoblastic leukemia.
Goodman PA; Wood CM; Vassilev A; Mao C; Uckun FM
Oncogene; 2001 Jul; 20(30):3969-78. PubMed ID: 11494125
[TBL] [Abstract][Full Text] [Related]
33. A novel recurrent NPM1-TYK2 gene fusion in cutaneous CD30-positive lymphoproliferative disorders.
Velusamy T; Kiel MJ; Sahasrabuddhe AA; Rolland D; Dixon CA; Bailey NG; Betz BL; Brown NA; Hristov AC; Wilcox RA; Miranda RN; Medeiros LJ; Jeon YK; Inamdar KV; Lim MS; Elenitoba-Johnson KS
Blood; 2014 Dec; 124(25):3768-71. PubMed ID: 25349176
[TBL] [Abstract][Full Text] [Related]
34. Down-modulation of type 1 interferon responses by receptor cross-competition for a shared Jak kinase.
Dondi E; Pattyn E; Lutfalla G; Van Ostade X; Uzé G; Pellegrini S; Tavernier J
J Biol Chem; 2001 Dec; 276(50):47004-12. PubMed ID: 11602573
[TBL] [Abstract][Full Text] [Related]
35. Anti-leukaemic activity of the TYK2 selective inhibitor NDI-031301 in T-cell acute lymphoblastic leukaemia.
Akahane K; Li Z; Etchin J; Berezovskaya A; Gjini E; Masse CE; Miao W; Rocnik J; Kapeller R; Greenwood JR; Tiv H; Sanda T; Weinstock DM; Look AT
Br J Haematol; 2017 Apr; 177(2):271-282. PubMed ID: 28295194
[TBL] [Abstract][Full Text] [Related]
36. The type 1 diabetes gene TYK2 regulates β-cell development and its responses to interferon-α.
Chandra V; Ibrahim H; Halliez C; Prasad RB; Vecchio F; Dwivedi OP; Kvist J; Balboa D; Saarimäki-Vire J; Montaser H; Barsby T; Lithovius V; Artner I; Gopalakrishnan S; Groop L; Mallone R; Eizirik DL; Otonkoski T
Nat Commun; 2022 Oct; 13(1):6363. PubMed ID: 36289205
[TBL] [Abstract][Full Text] [Related]
37. Identification of an indispensable role for tyrosine kinase 2 in CTL-mediated tumor surveillance.
Simma O; Zebedin E; Neugebauer N; Schellack C; Pilz A; Chang-Rodriguez S; Lingnau K; Weisz E; Putz EM; Pickl WF; Felzmann T; Müller M; Decker T; Sexl V; Stoiber D
Cancer Res; 2009 Jan; 69(1):203-11. PubMed ID: 19118004
[TBL] [Abstract][Full Text] [Related]
38. The Stat3-activating Tyk2 V678F mutant does not up-regulate signaling through the type I interferon receptor but confers ligand hypersensitivity to a homodimeric receptor.
Gakovic M; Ragimbeau J; Francois V; Constantinescu SN; Pellegrini S
J Biol Chem; 2008 Jul; 283(27):18522-9. PubMed ID: 18456658
[TBL] [Abstract][Full Text] [Related]
39. Transcriptome analysis reveals a major impact of JAK protein tyrosine kinase 2 (Tyk2) on the expression of interferon-responsive and metabolic genes.
Vogl C; Flatt T; Fuhrmann B; Hofmann E; Wallner B; Stiefvater R; Kovarik P; Strobl B; Müller M
BMC Genomics; 2010 Mar; 11():199. PubMed ID: 20338026
[TBL] [Abstract][Full Text] [Related]
40. Requirement of catalytically active Tyk2 and accessory signals for the induction of TRAIL mRNA by IFN-beta.
Rani MR; Pandalai S; Shrock J; Almasan A; Ransohoff RM
J Interferon Cytokine Res; 2007 Sep; 27(9):767-79. PubMed ID: 17892398
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
